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The novel avian inﬂuenza A H7N9 virus which caused the ﬁrst human infection in Shanghai,
China; was reported on the 31st of March 2013 before spreading rapidly to other Chinese
provinces and municipal cities. This is the ﬁrst time the low pathogenic avian inﬂuenza A
virus has caused human infections and deaths; with cases of severe respiratory disease
with pneumonia being reported.There were 440 conﬁrmed cases with 122 fatalities by 16
May 2014; with a fatality risk of∼28%.Themedian age of patientswas 61 yearswith amale-
to-female ratio of 2.4:1. The main source of infection was identiﬁed as exposure to poultry
and there is so far no deﬁnitive evidence of sustained person-to-person transmission. The
neuraminidase inhibitors, namely oseltamivir, zanamivir, and peramivir; have shown good
efﬁcacy in the management of the novel H7N9 virus. Treatment is recommended for all
hospitalized patients, and for conﬁrmed and probable outpatient cases; and should ideally
be initiated within 48 h of the onset of illness for the best outcome. Phylogenetic analysis
found that the novel H7N9 virus is avian in origin and evolved frommultiple reassortments of
at least four origins. Indeed the novel H7N9 virus acquired human adaptation via mutations
in its eight RNA gene segments. Enhanced surveillance and effective global control are
essential to prevent pandemic outbreaks of the novel H7N9 virus.
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INTRODUCTION
The inﬂuenzaA virus is amember of theOrthomyxoviridae family
that consists of an enveloped negative-sense, single-strandedRNA;
while its whole genome is made up of eight RNA gene segments.
The ﬁrst, second and third RNA segments are transcriptase-
associated proteins such as polymerase basic 1 (PB1), polymerase
basic 2 (PB2), and polymerase A (PA). The fourth, ﬁfth, sixth, sev-
enth, and eighth segments are hemagglutinin (HA), nucleocapsid
protein (NP), neuraminidase (NA), and membrane or matrix pro-
tein (M1 and M2), followed by non-structural proteins (NS1 and
NS2; Lamb and Choppin, 1983). InﬂuenzaA viruses can evolve via
reassortment, which is the exchanging and mixing of eight RNA
gene segments from two different inﬂuenza strains in a single host
to form a new inﬂuenza virus (Liu et al., 2013a). Furthermore,
Inﬂuenza A viruses are categorized into different subtypes based
on the combination of two surface proteins, which is hemagglu-
tinin andNA.There are currentlyH1 toH18 andN2 toN10 surface
proteins identiﬁed (Nagy et al., 2012; Chen et al., 2013; Shi et al.,
2013a; To et al., 2013).
The novel avian-origin inﬂuenza A virus that is known as the
H7N9 virus and caused severe and fatal respiratory disease was
identiﬁed in Shanghai, China (Li et al., 2014). Although many
avian inﬂuenza virus subtypes such asH5N1,H7N1,H7N7,H7N2,
H7N3, and H9N2 were found to be capable of infecting humans;
the lowpathogenic avian inﬂuenzaAH7N9 virus had never caused
human infections with a fatal outcome until the outbreak in Qi
et al. (2013),Richard et al. (2013), and Shi et al. (2013a). This novel
H7N9 virus is the ﬁrst H7N9 subtype to cause human infections,
and by May 16 2014 had caused a total of 440 human infections
including 122deaths (Watanabe et al., 2014). In contrast, this novel
virus is lowly pathogenic in poultry (Richard et al., 2013); which
is the main source of infection (Li et al., 2014). This literature
reviewwill discuss the epidemiology, origin and diversity, virology,
clinical characteristics, treatment, control, and prevention of the
novel H7N9 virus.
EPIDEMIOLOGICAL CHARACTERISTICS
The ﬁrst human case was reported in Shanghai on the 31st of
March 2013 (CDC, 2014). Shanghai was affected the most by
this novel virus due to its location along the Asian-Australian
ﬂyway, where migratory birds transit at the wetlands. This city
also has the highest densities of both people and poultry (Bing-
sheng and Yijun, 2007). After the emergence of the infection in
Shanghai, subsequent cases were detected in neighboring cities
such as Jiangsu, Zhejiang, and Anhui around the lower Yangtze
River delta in the following months (Figure 1; Liu et al., 2013a).
This novel virus then spread to other regions of China such as
Beijing, Henan, Hunan, Jiangxi, Fujian, and Shandong (But-
ler, 2013). However, among all the provinces, most cases were
reported in Shanghai, Zhejiang and Jiangsu; provinces located
in the eastern part of China (Peng et al., 2013). There was no
H7N9 infection cases found in other countries outside China
except for one case that was reported in Taipei on the 24th of
April, whereby the patient had recently returned from Jiangsu
(Chang et al., 2013). Previously, H7N9 viruses were found in
chickens in the USA (Pasick et al., 2012) and birds in South Korea
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FIGURE 1 |The geographic areas of confirmed cases of human infection
with avian influenza A H7N9 virus, as of 16 May 2014 (total of 440 cases).
The number of cases in each province is based on data reported by the Centre
for Health Protection, Hong Kong PRC SAR (http://www.chp.gov.hk/en/
index.html). The darker the blue color, the higher the number of cases. One
case detected in Malaysia was not shown in this ﬁgure.
(Kim et al., 2012). However, it had never caused human infec-
tions until the outbreak in 2013 (Qi et al., 2013; Richard et al.,
2013; Shi et al., 2013a; Li et al., 2014). Kageyama et al. (2013)
reported that H7 subtypes have never caused fatal cases except
the H7N7 subtype, which caused one fatality in the Netherlands
in 2003; while human infections with the N9 subtype had never
been reported in any country (Gao et al., 2013a; Liu et al., 2013a;
Shi et al., 2013a).
Toward the end of April 2013, the human cases of H7N9
infections increased signiﬁcantly, reaching 125 conﬁrmed cases.
Researchers detected that themain source of theH7N9 virus infec-
tion was through exposure to infected live poultry markets or
contaminated surroundings (Chen et al., 2013; Peng et al., 2013;
Richard et al., 2013; Shi et al., 2013b; van Riel et al., 2013). This
prompted the Chinese government to suspend live poultry mar-
kets in many provinces such as Shanghai and Zhejiang (Murhekar
et al., 2013; Xu et al., 2013a); and halt the trading of live birds
carrying the virus. These measures effectively prevented further
spread of the virus as a rapid decline in new human H7N9 infec-
tions was observed during the following 2 weeks (Chowell et al.,
2013; Yu et al., 2013). The number of conﬁrmed human H7N9
cases increased signiﬁcantly, however, in January and February
2014, with more than 30 new cases over several consecutive weeks
(WHO, 2013). This could possibly be as a result of the fall in
temperature in the winter of 2013, and/or the reopening of the
live poultry markets (Watanabe et al., 2014). By the 16th of May
2014, a total of 440 human H7N9 cases were conﬁrmed with
122 associated deaths (unofﬁcial statement1). Of these, 425 cases
occurred in China2, while the remaining 15 were exported cases3
(Figure 1).
The age of infected patients ranged from 2 to 91 years old while
most of them were older instead of young adults with a median age
of 61 years. Recent studies reported that patients weremostly older
adults due to several factors. Firstly, children with H7N9 presented
mostly withmild or asymptomatic infections thatmight have been
under diagnosed (Mei et al., 2013; Xu et al., 2013b). Secondly,most
of the adult patients were poultry workers or visitors who had
prolonged exposure to the H7N9 virus in a larger dose. Moreover,
researchers found that older adults have a higher risk of comorbid
illnesses and a weaker immune response toward the H7N9 virus
due to the immunological phenomenon of ‘original antigenic sin’
(Kim et al., 2009; Skowronski et al., 2013). However, population
immunity toward this novel H7N9 virus is low as it only emerged
recently. Hence, individuals of any age are susceptible to it (Shi
et al., 2013b; Li et al., 2014).
Most of the infected individuals were males, with a male-
to-female ratio in urban and rural areas of 2.4:1 and 1.6:1
1http://www.cidrap.umn.edu/sites/default/ﬁles/public/downloads/topics/cidrap
_h7n9_update_051614_0.pdf
2http://www.info.gov.hk/gia/general/201405/17/P201405170325.htm
3http://www.chp.gov.hk/ﬁles/pdf/2014_avian_inﬂuenza_report_vol10_wk19.pdf
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respectively. This was mostly due to gender-based differences
in exposure to poultry as opposed to differences in immu-
nity (WHO, 2013). Additionally, older men were found to be
weaker than older women due to their shorter mean life-span
(Zhuang et al., 2013). However, Liu et al. (2013b) found that
susceptibility toward the novel H7N9 virus was not affected
by gender, race, occupation, income level, and educational
background.
It was noted that more than two- thirds of infected patients
had occupational or recent exposure to poultry in the 7 days
before the onset of illness (Shi et al., 2013a; van Riel et al., 2013).
This was further supported when gene sequences which were
highly similar to the H7N9 virus were found in ducks, chickens,
pigeons and environmental samples from live poultry markets
in affected regions in China. More studies should be done to
investigate the possibility of human H7N9 infections caused
by the consumption of inadequately cooked poultry products
and contact with wild birds, as documentation of such cases is
insufﬁcient.
To date there is no deﬁnitive evidence on sustained person-to-
person transmissions, although two family clusters were reported.
Thiswas because therewere no other cases reported amonghealth-
care workers or those in close contact with infected patients
(Ramos et al., 2013; van Riel et al., 2013; Yu et al., 2013). More-
over, H7N9 human cases were discovered in different areas of
China and were not epidemiologically related (Gao et al., 2013a;
Richard et al., 2013). Some researchers also reported that most of
the H7N9 patients with severe or fatal cases were obese, smokers,
chronic drug users, had comorbidities, lung or immunosuppres-
sive diseases; delayed antivirus treatments, and increasing age
(Gao et al., 2013a; Peng et al., 2013; Shi et al., 2013a). Stud-
ies have also found that infected patients who have a higher
risk of complications such as acute respiratory distress syn-
drome (ARDS) and respiratory failure, were those who were less
than 5 years or more than 64 years of age; or those who had
underlying medical illnesses (Li et al., 2014). It has also been pos-
tulated that this novel H7N9 virus might have a seasonal pattern,
given that the number of human H7N9 cases dwindled over the
summer after its peak in spring, between March 28 and April
18 in Liu et al. (2013c). An increase, however, was noted in
early October 2013, at which more new H7N9 infections were
reported, coinciding with the arrival of winter in China (CDC,
2014).
One of the reasons for the emergence of the novel H7N9 virus
that caused a human epidemic in China is the high population
of human and poultry (van Riel et al., 2013). Given that the
novel H7N9 virus originated from live poultry markets that gather
many different types of wild birds and poultry species, reassort-
ment could occur easily among the different subtypes of avian
inﬂuenza viruses to produce the novel H7N9 virus (Chang et al.,
2013; Chen et al., 2013; Gao et al., 2013b; Liu et al., 2013a; Xiong
et al., 2013a). Furthermore, the selective pressure induced by the
widespread use of the H5N1 vaccine could cause the emergence of
the H7N9 virus, as H5 and H7 are the common subtypes that gen-
erally cause poultry outbreaks. China uses more than 90% of the
H5N1 vaccine worldwide (Swayne, 2012). While the H5 vaccine
efﬁciently restrains the circulating clade of H5 virus in China, this
vaccine is unable to prevent the emergence of antigenically drifted
H5 and non-H5 viruses. Furthermore, poor biosecurity measures
at farms and wet markets permit the easy intrusion and strength-
ening of a new virus reassortant. The mechanism of spread of the
H7N9 outbreak in 2013 between different geographical regions,
however, remains unclear; and as such speculation over the roles
of migratory birds, poultry and human beings warrant further
investigation.
ORIGIN AND DIVERSITY
Phylogenetic studies have shown that the novel H7N9 virus is
avian in origin and is a result of multiple reassortments of avian
inﬂuenza viruses from at least four origins (Figures 2 and 3; Gao
et al., 2013b; Liu et al., 2013a). The gene encoding forHAof theH7
subtype was most closely related to the avian inﬂuenza A H7N3
viruses from domestic ducks in Zhejiang (Figure 2A); while the
NA gene segment of the N9 subtype was most closely related to
H7N9 viruses from wild birds in South Korea (Figure 2B); and
six internal genes originated from two different groups of avian
inﬂuenzaAH9N2 viruses in brambling birds or chickens in Shang-
hai, Zhejiang or Beijing, China (Figure 3; Kageyama et al., 2013;
Knepper et al., 2013; Liu et al., 2013a; Peng et al., 2013; Qi et al.,
2013; Richard et al., 2013; Shi et al., 2013a,b; Tharakaraman et al.,
2013; Watanabe et al., 2013; WHO, 2013; Li et al., 2014). Many
researchers indicated that the internal genes of this novel virus
which are PA, PB1, and PB2; originated from the H9N2 virus
from bramblings in Beijing (Figure 3A); while M, NP and NS
genes originated from the H9N2 virus from chickens in eastern
China (Figure 3B; Chang et al., 2013; Chen et al., 2013; Gao et al.,
2013b; Liu et al., 2013a; Xiong et al., 2013a). Furthermore, all stud-
ies found that gene reassortment happened in an avian host since
all 8 gene segments of novel H7N9 viruses are avian in origin
(Figures 2 and 3; Chang et al., 2013; Chen et al., 2013; Gao et al.,
2013b; Liu et al., 2013a; To et al., 2013; Xiong et al., 2013a). Studies
have also reported that all the isolated novel H7N9 strains share a
common ancestor as they consist of highly similar nucleotide and
amino acid sequences based on genetic analysis (Kageyama et al.,
2013).
The novel H7N9 virus originated from new virus reassortants,
at which each of the hemagglutinin, NA and internal genes from
H7N3,H7N9, andH9N2 viruses respectively (Figures 2 and 3) cir-
culated silently in domestic poultry for a period of time, and then
reasserted silently to form this novel H7N9 virus; which gained
the ability to infect human beings in the Yangtze River Delta (Peng
et al., 2013; WHO, 2013).
Mammalian adaptation of the novel H7N9 virus might be
acquired via mutations and genetic changes that occurred in
domestic poultry to cause poultry- to- human transmissions
(Shi et al., 2013a). Apart from that, novel H7N9 strains iso-
lated from the ﬁrst patient (A/Shanghai/1/2013) were found to
be phylogenetically different from other human and avian iso-
lates found later. This proved that this new reassortant obtained
this degree of diversity after circulating for a period of time,
and also showed that there were two or more introductions into
humans. It is thus postulated that further adaptation could lead to
less symptomatic infection and more efﬁcient person-to-person
transmission.
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FIGURE 2 | Phylogenetic trees of H7 (A) and N9 (B).The H7N9 viruses are shown by red lines and text. D, duck;W, wild bird; H, human being; T, turkey; G,
goose. Adapted from Liu et al. (2013a).
VIROLOGY
Many researchers have indicated that the novel H7N9 virus could
cross-species from poultry to humans and increase the pandemic
risk as it possesses mammalian adaptation by having mutations
in the receptor binding site of the hemagglutinin gene, where
Gln226Leu and Gly186Val substitutions in the hemagglutinin
gene have caused higher binding afﬁnities toward human α-
2,6-linked sialic acid receptors in the human upper respiratory
tract (Table 1; Connor et al., 1994; Ha et al., 2001; Chutinim-
itkul et al., 2010; Wang et al., 2010; Gambaryan et al., 2012; Herfst
et al., 2012; Xiong et al., 2013b). To et al. (2013) indicated that
human Inﬂuenza A viruses bind preferentially to α-2,6-linked
sialic acid receptors which are abundant in the human upper res-
piratory tract, while avian inﬂuenza A viruses with 226Glu have
higher afﬁnities to avian α-2,3-linked sialic acid receptors in the
human lower respiratory tract and avian alimentary tract (Shi
et al., 2013c). Hence, the novel H7N9 virus changed its receptor
binding properties from avian-type to human-type, which could
increase air transmission and pandemic potential. Some novel
H7N9 strains have Thr160Ala mutation in the hemagglutinin gene
that causes the absence of an N-glycosylation site at position 158
and increases the afﬁnity for human receptors (Table 1;Wang et al.,
2010). Some studies showed that the novel H7N9 virus retains its
high afﬁnity toward avian α-2,3-linked sialic acid receptors while
having a low but signiﬁcantly higher afﬁnity to α-2,6-linked sialic
acids as compared to other avian H7 subtypes (Dortmans et al.,
2013; Ramos et al., 2013). As a result, this novel virus is able to
cause avian-to-human transmission by circulating in poultry and
binding to the human lower respiratory tract that consists of these
twodifferent receptors (Shi et al., 2013a). In short, this novelH7N9
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FIGURE 3 | Phylogenetic trees of PB2 (A) and NS (B). Avian inﬂuenza A H7N9 viruses are shown in red, brambling viruses in pink, viruses isolated from
Shanghai in 2012 in blue, and viruses isolated from Jiangsu province in green. Adapted from Liu et al. (2013a).
virus consists of the viral-attachment characteristics of both avian
and human inﬂuenza A viruses, which have never been identiﬁed
in other avian inﬂuenza A viruses. However, further investiga-
tion is essential as the novel H7N9 strain A/Shanghai/1/2013 from
the ﬁrst patient did not contain the Gln226Leu mutation but
nevertheless had the ability to cause human infections.
There was also a mutation in the PB2 gene segment of the
novel H7N9 virus which is responsible for host speciﬁcity at
which avian-characteristic E (Glutamic acid) at position 627 of
PB2 is mutated to human-characteristic K (lysine), which would
enhance viral replication and polymerase activity (Dortmans et al.,
2013; Kageyama et al., 2013; Knepper et al., 2013; Tharakara-
man et al., 2013). Studies showed that the novel H7N9 virus with
E627K in PB2 gene caused more efﬁcient viral RNA replications
at a lower temperature (33◦C), which is the human nasal body
temperature, as compared to inﬂuenza avian viruses with 627E
(Table 1; Hatta et al., 2001; Labadie et al., 2007; Dortmans et al.,
2013; Knepper et al., 2013; Tharakaraman et al., 2013). Indeed
researchers found that the E627K mutation is associated with an
increased virulence of the H5N1 virus that is highly pathogenic
(Hatta et al., 2001; Labadie et al., 2007). Mutations of both E627K
and Asp701Asn in PB2 genes also caused mammalian adaptation
of the novel H7N9 virus and efﬁcient respiratory-droplet trans-
mission (Table 1; Hatta et al., 2001; Li et al., 2005; Labadie et al.,
2007; Gao et al., 2009; Neumann et al., 2012). Moreover, Leu89Val
mutation was also detected in the PB2 gene of this novel H7N9
virus that enhanced polymerase activity (Table 1; Hatta et al.,
2001; Labadie et al., 2007). Additionally, Qi et al. (2014) stated
that this novel virus also consists of other human-like signatures
such as PA-V100A,PA-K356R, and PA-S409N. However, this novel
virus mainly consists of more avian-like residues at signature posi-
tions (Qi et al., 2014). Researchers reported that genetic variations
in the viral ribonucleoprotein (RNP) complex which consists of
PB2, PB1, and PA; would improve cross-species transmission to
humans. For instance,mutations of R591Q, andN701D in the PB2
gene have been found to alter host cell tropism (Qi et al., 2014).
Past research also revealed that this novel H7N9 virus consists of
a full-length of PB1-F2 protein, which is 90 amino acids; which
then results in increased virulence (Table 1; Zamarin et al., 2006).
There were no multibasic amino acids detected but a single
amino acid R at the proteolytic cleavage site of its hemagglutinin
gene, which caused this novel virus to display low pathogenicity
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Table 1 | Importance of the key genetic mutations in viral proteins of influenza A H7N9 viruses in the year 2013.
Gene Mutation Importance of the mutation Reference
Hemagglutinin (H3
numbering)
Gln226Leu Increased binding afﬁnity to α-2,6-linked
sialic acid receptor
Connor et al. (1994), Ha et al. (2001),
Chutinimitkul et al. (2010), Herfst et al.
(2012)
Gly186Val Increased binding afﬁnity to α-2,6-linked
sialic acid receptor
Gambaryan et al. (2012), Xiong et al. (2013b)
Thr160Ala Increased binding afﬁnity to α-2,6-linked
sialic acid receptor
Wang et al. (2010)
Multibasic amino acid at HA0
cleavage site
Cleavage by ubiquitous proteases Senne et al. (1996), Subbarao et al. (2003)
Neuraminidase (viral release
from host cell surface)
Arg292Lys Neuraminidase resistance Gubareva et al. (1997), McKimm-Breschkin
et al. (1998)
Deletions in stalk region Increased virulence Matrosovich et al. (1999)
PB2 (viral replication) Asp701Asn Mammalian adaptation Li et al. (2005), Gao et al. (2009)
Leu89Val Enhanced polymerase activity Hatta et al. (2001), Labadie et al. (2007)
E627K Enhanced viral replication and virulence in
mice model
Hatta et al. (2001), Labadie et al. (2007)
PB1 (viral replication) Ile368Val Enables droplet transmission in ferrets Herfst et al. (2012)
PB1-F2 (induce cellular
apoptosis and inhibit
function of type I interferon)
Full-length Full-length PB1-F2 needed for virulence in
mice
Zamarin et al. (2006)
Matrix protein M1 (viral
assembly and budding)
Asn30Asp
Thr215Ala
Increased virulence in a mice model
Increased virulence in a mice model
Fan et al. (2009)
Fan et al. (2009)
Matrix protein M2 Ser31Asn Amantadine resistance Hay et al. (1985), Pinto et al. (1992)
NS1 (counteracts host
antiviral response)
Pro42Ser
Deletion of PDZ-binding motif
Increased virulence in mice Signaling of
host proteins
Jiao et al. (2008)
Jackson et al. (2008)
in poultry (Table 1; Senne et al., 1996; Subbarao et al., 2003).
This multibasic amino acid motif is a key virulence marker for
highly pathogenic avian inﬂuenza subtypes H5 and H7 (Senne
et al., 1996; Subbarao et al., 2003). Therefore, the novel H7N9
virus has the potential to cause an even more disastrous pan-
demic via subsequent mutations to acquire multibasic amino
acid motifs since it is already highly pathogenic among humans
without multibasic amino acids. Experimental studies reported
that there were ﬁve amino acid deletions at positions 69–73 in
the stalk region of NA which caused enhancement in poultry
adaptation as viral virulence is associated with the stalk length
(Matrosovich et al., 1999). Researchers found that a premature
stop codon near the C-terminus of NS1 gene segment caused PDZ
domain-binding motif deletion, which attenuates novel H7N9 in
mammals (Table 1; Jackson et al., 2008). Studies also found that
some novel H7N9 strains such as A/Shanghai/1/2013, consisted
of Arg292Lys-resistant mutation in the NA gene; which reduced
susceptibility to NA inhibitors (NIs) such as zanamivir by 30-fold,
and oseltamivir by 100-fold based on a ﬂuorescence-based NA
inhibition assay (Gubareva et al., 1997; McKimm-Breschkin et al.,
1998, 2003; Table 1). However, only one H7N9 strain consisted
of Arg292Lys based on current research (McKimm-Breschkin,
2013). Hence, NIs are still used as ﬁrst-line drugs in treatment
as genetic analysis, phenotypic assessment, NA inhibition assay,
and in vitro testing have conﬁrmed the sensitivity of most strains
of H7N9 to oseltamivir and zanamivir (Peng et al., 2013; Shi
et al., 2013a; WHO, 2013). In some patients treated with NA
inhibitors, resistant H7N9 variants have been detected encod-
ing R292K mutation in NA that confers resistance to oseltamivir
(Hu et al., 2013; Wu et al., 2013; Yen et al., 2013; Lin et al., 2014;
Shen et al., 2014). Usually the oseltamivir-resistant (NA-R292K)
mutations cause reduced viral ﬁtness (Govorkova, 2013); but
a study by Hai et al. (2013) did not detect the effect of the
NA-R292K mutations in an H7N9 virus in regard to its viru-
lence in mice, thus suggesting that oseltamivir-resistant H7N9
viruses could be competitive in nature. Therefore the continu-
ous surveillance of oseltamivir-susceptibility is essential. Further
investigations are also needed as it was found that corticosteroid
therapy caused the presence of Arg292Lys mutation in patients (Li
et al., 2014).
Researchers successfully identiﬁed Asn30Asp and Thr215Ala
mutations in the M1 protein of all isolated H7N9 strains which
resulted in increased viral virulence (Fan et al., 2009). Moreover,
the viral M2 gene of the novel H7N9 consisted of a Ser31Asn
mutation that conferred resistance toward M2 channel blockers,
amantadine and rimantadine (Table 1; Hay et al., 1985; Pinto et al.,
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1992). Furthermore, the six internal genes of the novel H7N9
virus originated from the H9N2 virus that caused this novel virus
to have a severe pathogenesis. This was because the H9N2 virus
could induce prominent cytokine and chemokine activation in
epithelial cells and marcrophages of humans (Shi et al., 2013a).
Researchers also discovered that the novel H7N9 virus replicates
more efﬁciently at the human lower respiratory tract which con-
sists of both 2,3-linked and α-2,6-linked sialic acid receptors (Shi
et al., 2013a). Furthermore, studies showed that the novel H7N9
virus reproduces efﬁciently in human alveolar tissue as its NS1
protein suppresses the response of antiviral beta interferon-type I,
which then causes severe lower respiratory tract diseases in infected
individuals (Knepper et al., 2013). Moreover, Pro42Ser mutation
was identiﬁed in its NS1, which increased viral virulence (Table 1;
Jiao et al., 2008).
There is, however, no sustainedhuman-to-human transmission
of the novel H7N9 even though it has acquired human adap-
tation (Richard et al., 2013). Recent studies also indicated that
avian H7N9 tends to bind to lower pulmonary epithelial cells
where both α-2,3-linked and α-2,6-linked sialic acid receptors are
present, instead of the epithelial cells of the upper respiratory
tract; which makes it incapable of causing a pandemic, respiratory
droplet-based transmission and efﬁcient transmission between
humans (Qi et al., 2013; van Riel et al., 2013). Other studies dis-
covered that the novel H7N9 virus binds inefﬁciently to human
tracheal epithelial cells as compared to seasonal or pandemic avian
inﬂuenza viruses, which blocks human-to-human transmission
(Dortmans et al., 2013). Furthermore, researchers indicated that
this novel H7N9 virus is incapable of causing human-to-human
transmission because it possess a high pH for the fusion of the
hemagglutinin gene, which results in lower thermostability and
hemagglutinin stability (Richard et al., 2013).
Therefore, this novel H7N9 virus needs to mutate key signa-
ture amino acid residues in the protein functional domains in
order to achieve avian-to-human transmission. All ﬁndings state
that the novel H7N9 virus remains lowly pathogenic and unde-
tectable in poultry. This would create an infection reservoir that
increases the potential of the novel H7N9 virus to evolve silently
and become highly pathogenic in both poultry and humans in
the future (Gao et al., 2013b). Based on these ﬁndings, compre-
hensive and enhanced surveillance is essential among poultry and
humans tomonitor the evolution andmutation of the novelH7N9
virus that might cause a pandemic outbreak due to highly efﬁcient
human-to-human transmission with asymptomatic infections in
the future.
CLINICAL CHARACTERISTICS
It was found that more than 70% of infected patients had exposure
to poultry 3–8 days before the onset of illness (Shi et al., 2013a).
Initial symptoms observed were generally similar to H1N1 and
H5N1 virus infections such as fever, inﬂuenza-like illness, and
symptoms of lower respiratory tract infection such as productive
cough, sputum and dyspnoea (Gao et al., 2013a; Peng et al., 2013;
Shi et al., 2013a;WHO,2013). Typical and atypical antibioticswere
also not effective at treating progressive pneumonia in infected
patients (Shi et al., 2013a; To et al., 2013). This novel virus pre-
dominantly affects the human lower respiratory tract (Shi et al.,
2013a); and studies have found that patients who start their treat-
ment later than 5 days after the onset of illness tended to have
moderate or severe ARDS (Gao et al., 2013a).
Laboratory investigations revealed that patients had lym-
phopenia, leucopenia, thrombocytopenia, impaired renal or liver
function, hypoxaemia, high chemokine concentrations or serum
cytokine, high D-dimer concentrations, disseminated intravascu-
lar coagulation, and leucocytosis with neutrophilia as the disease
progressed (Lu et al., 2013; Shi et al., 2013a; To et al., 2013; WHO,
2013). The white blood cell count in infected patients was found
to be normal or slight lower at the initial stage (Gao et al.,
2013a; Lu et al., 2013; Shi et al., 2013b); while the concentra-
tions of C-reactive protein, hepatic aminotransferases, creatine
kinase isoenzymes, and lactate dehydrogenase or creatine kinase
were raised at some stage of the disease (Gao et al., 2013a; Shi
et al., 2013a,b). Furthermore, results from CT scans and chest
radiographs revealed diffuse alveolar opacities, multi-lobar patchy
consolidation,mediastinal emphysema, and pleural effusions with
ground glass changes in infected patients (Gao et al., 2013a; Lu
et al., 2013; Shi et al., 2013a,b; To et al., 2013; WHO, 2013).
The most common complications noted were ARDS, respiratory
failure, refractory hypoxemia, encephalopathy, rhabdomyolysis,
multiorgan dysfunction syndrome, secondary bacterial infections,
and septic shock which could lead to death (Peng et al., 2013;
Shi et al., 2013a,b; To et al., 2013; WHO, 2013). Other than that,
clinical investigation found that lymphocytopenia and thrombo-
cytopenia were prognostic indicators of ARDS and death, while
most of the infected H7N9 patients died because of refractory
hypoxemia (Gao et al., 2013a). The level of C-reactive protein is
also used as a clinical marker for illness severity of human H7N9
infections (Shi et al., 2013a).
The novel H7N9 virus has an estimated mean incubation
period of approximately 3 days, and more than 95% of infected
individuals displayed symptomswithin aweek of infection. There-
fore, the medical surveillance and quarantine implemented on
close contacts should be reduced to less than 1 week. The fatality
risk was about 33% based on conﬁrmed laboratory-cases (Cowl-
ing et al., 2013). The virus has a median time from illness onset
to admission, from illness onset to laboratory conﬁrmation, from
hospital admission to discharge, and from hospital admission to
death of about 4.5, 8.3, 41.7, and 11 days respectively (Cowl-
ing et al., 2013; WHO, 2013). These statistics, however, should
not be applied globally to other countries since these estimations
would be different based on the medical advancement in different
countries. For instance, countries with more advanced surveil-
lance systems and medical services will be able to detect this novel
virus in a shorter time, sustain the life of patients for a longer time,
as well as shorten the recovery period.
TREATMENT, CONTROL, AND PREVENTION
There is currently no effective vaccine available for the manage-
ment of this virus (Qi et al., 2014). According to several ran-
domized clinical trials involving the pediatric, adult and geriatric
populations; the NA inhibitors, namely oseltamivir, zanamivir,
and peramivir; have shown good efﬁcacy in the management of
the novel H7N9 virus (Hayden et al., 1997, 1998, 1999; Monto
et al., 1999; Hedrick et al., 2000; Nicholson et al., 2000; Treanor
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et al., 2000; Lalezari et al., 2001; Whitley et al., 2001; Sato et al.,
2005; Cowling et al., 2010; Heinonen et al., 2010; Yu et al., 2010;
Hernán and Lipsitch, 2011). However, the novel H7N9 virus con-
fers resistance to both rimantadine and amantadine which are
M2-ion channel blockers, and as such they are not recommended
for use in treatment (Li et al., 2014; Qi et al., 2014). Previous stud-
ies using hyperimmune IV immunoglobulin for the treatment of
severe inﬂuenza A (H1N1) infection resulted in a lower viral load
and reduced mortality (Zheng et al., 2008). This prompted investi-
gators to propose the role of such a treatment for the management
of severe H7N9 illness as well (Shi et al., 2013a).
According to the guidelines released based on recommenda-
tions from the World Health Organization (WHO) and Centers
forDiseaseControl andPrevention (CDC), treatment iswarranted
for all hospitalized patients, and for conﬁrmed and probable out-
patient cases. Treatment should ideally be initiated within 48 h of
the onset of illness as it has been shown to reduce disease severity
as well as mortality (Jain et al., 2009; Siston et al., 2010; Hiba et al.,
2011; Kumar, 2011; Rodríguez et al., 2011; Yu et al., 2011; Chemaly
et al., 2012; Hsu et al., 2012; Louie et al., 2012; Muthuri et al., 2013).
However, treatment should be initiated even if 48 h has lapsed. For
uncomplicated illness, the recommended dose is two doses per day
of an NA inhibitor medication, for a period of 5 days. For patients
with severe or complicated illness, treatment with oral or enteri-
cally administered oseltamivir is recommended, however, data is
currently lacking as to the duration of treatment. The CDC in the
meantime has currently recommended a longer course of treat-
ment, i.e., 10 days, pending further investigations. Real time-PCR
or rapid point-of-care tests which could detect inﬂuenza A virus
infection, are used for starting antiviral treatments earlier before
the subtype is determined. Currently, real time-PCR is used to
detect and conﬁrm novel H7N9 infections (Shi et al., 2013b).
Some control measures should be taken to prevent further
animal-to-person transmission such as the temporary closure of
live poultry and bird markets in infected regions. Indeed the clo-
sure of live poultry markets was found to reduce human H7N9
infections drastically in affected provinces over the summer in Liu
et al. (2013c) and Yu et al. (2013). Besides that, improved biosecu-
rity in animal husbandry, comprehensive surveillance, vaccination
programs, poultry culling, disinfection, and the segregation of dif-
ferent species in poultry markets are essential in order to prevent
the novel H7N9 virus from evolving and causing a pandemic (Liu
et al., 2013a; Shi et al., 2013a; Li et al., 2014). Moreover, live poultry
should not be kept overnight and regular rest days for live poultry
markets should be implemented (Yu et al., 2013). Some mea-
sures such as immediate isolation of infected patients, progressive
monitoring of close contacts, and standard safety guidelines for
healthcare workers are essential even though there is no sustained
human-to-human transmission (Li et al., 2014).
In the long term, a multi-sectoral approach that studies the
interrelated relationship between the emergence and transmission
of the novel H7N9 virus with the cultural, biological, economic,
social, and environmental factors should be highlighted. This
is to restructure the system of live poultry market instead of
destabilizing them. For example, changes should be made to the
practice of poultry trading and purchasing. Food security can then
be ensured while the risk of disease transmission can be decreased.
CONCLUSION
In conclusion, an immediate pandemic outbreak of the novel
H7N9 virus among humans is unlikely to happen, based on the
aboveﬁndings,which showed that this novel virus has not acquired
all the characteristics of previous human avian inﬂuenza viruses
that caused efﬁcient human-to-human transmissions. However,
these viruses have shown the capability of acquiring mammalian-
adapting amino acid changes, thus enabling them to reassort with
circulating human viruses (Zhu et al., 2013b). The occurrence of
high ﬁtness of oseltamivir-resistant H7N9 viruses also deﬁnitely
poses a signiﬁcant threat to humans (Richard et al., 2013; Zhu et al.,
2013a). Therefore enhanced surveillance is essential to continue
monitoring and characterizing this novel H7N9 virus in order to
have a better understanding of the molecular mechanisms which
enable the crossing of the species barrier, and identifying the pos-
sibility of airborne transmission between humans; to prevent a
pandemic outbreak in the future. Medical surveillance and ser-
vices must also be improved to ensure early detection of human
H7N9 infections in order to have a higher rate of recovery. There
is currently no vaccine available and NIs are the main antiviral
treatments used. Further studies on antiviral treatments and vac-
cines are essential in order to reduce the associated morbidity and
mortality. Moreover, the biosecurity and hygiene of live poultry
markets and farms which act as the main source of novel H7N9
infections have to be improved and updated from time to time.
This is to stop the human epidemic while preventing the novel
H7N9 virus from circulating, spreading, maintaining, and reas-
sorting to evolve as a more pathogenic avian inﬂuenza A virus or
a pandemic agent.
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